Kedrion alongside IPOPI at the IPIC Congress in Madrid
The importance of early diagnosis and the most recent innovations in the treatment of PID patients were the focus
Kedrion keeps Hemophilia therapy debate flowing in Latin America
A recent CLAHT Congress symposium restates current and future role of replacement therapy
FSI SGR enters Kedrion share capital
The company continues with its growth and development strategy
Kedrion submits to FDA for Manufacture of RhoGAM/MICRhoGAM in Melville, NY
On Sep 30, 2019 Kedrion Biopharma Inc. (Kedrion Biopharma) met another milestone towards transferring the drug manufacture of RhoGAM/MICRhoGAM from Ortho Clinical Diagnostics (OCD), Raritan, NJ to Kedrion Biopharma’s Melville, NY facility. A robust Prior Approval Supplement (PAS) package was submitted and acknowledged by the FDA for review. The Prescription Drug User Fee Act (PDUFA)
Kedrion reaffirms its commitment for the global eradication of Rh disease
A worldwide initiative for maternal and fetal health launches in Florence, Italy
Leading medical-scientific event on Hemophilia held in Trieste, Italy
Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight
Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy
A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN
First patient enrolled and treated in Kedrion’s CARES10 clinical study
Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients
June 27 and 28 in Trieste (Italy), a two-day event dedicated to hemophilia
Replacement therapy, personalization and access to treatment are the main themes of the congress organized by Kedrion